Elevation Oncology, Inc.
ELEV · NASDAQ
3/31/2025 | 12/31/2024 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -100% | – | – | – |
| Gross Profit | -$0 | $0 | -$0 | -$0 |
| % Margin | – | 50% | – | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -24,905.3% | – | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -27,463.2% | – | – |
| EPS Diluted | -0.24 | -0.18 | -0.22 | -0.18 |
| % Growth | -33.3% | 18.2% | -22.2% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | -$0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | $0 |